Please check your internet connection and try again.
# Ecospirin (Aspirin, Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of acetylsalicylic acid (ASA), an NSAID that irreversibly inhibits cyclooxygenase (COX)-1 and COX-2 enzymes. Enteric coating is designed to bypass gastric absorption to reduce direct mucosal irritation, though it does not eliminate systemic risk of peptic ulceration.
## Primary Indications
* Secondary prevention of myocardial infarction (MI) and stroke.
* Acute coronary syndrome (ACS).
* Management of stable or unstable angina.
* Prophylaxis against venous thromboembolism (in specific populations).
## Adult Dosing
* **Acute Coronary Syndrome:** 160–325 mg (non-enteric coated preferred for initial loading to ensure rapid absorption; chewable).
* **Secondary Prevention/Maintenance:** 75–100 mg daily.
* **Maximum Dose:** Generally 325 mg/day for antiplatelet indications.
## Pediatric Dosing
* **Kawasaki Disease:** 80–100 mg/kg/day divided every 6 hours (acute phase), then 3–5 mg/kg once daily (convalescent phase).
* **Note:** Use in children/adolescents for viral infections (e.g., flu, chickenpox) is **strictly contraindicated** due to the risk of Reye's syndrome.
## Dose Adjustments
* **Renal Impairment:** Reduce dose or avoid if CrCl < 10 mL/min.
* **Hepatic Impairment:** Avoid in severe hepatic failure due to potential for impaired clotting factor synthesis and increased bleeding risk.
## Contraindications
* Hypersensitivity to salicylates or other NSAIDs.
* Active peptic ulcer disease or pathological bleeding.
* Asthma with nasal polyps (triad asthma).
* Children/teenagers with viral infections (Reye’s syndrome risk).
* Third-trimester pregnancy.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, gastric mucosal erosion, occult bleeding.
* **Hematologic:** Increased bleeding risk (prolonged bleeding time).
* **Allergic:** Urticaria, anaphylaxis, bronchospasm.
* **Otologic:** Tinnitus and hearing loss (usually signs of toxicity).
## Key Drug Interactions
* **NSAIDs (e.g., Ibuprofen):** May interfere with the antiplatelet effect; avoid concomitant use.
* **Anticoagulants (Warfarin, DOACs, Heparin):** Significant additive bleeding risk.
* **Antiplatelets (Clopidogrel, Ticagrelor):** Used intentionally, but increases bleeding risk.
* **SSRIs/SNRIs:** Increased risk of upper GI bleeding.
## Monitoring
* **Baseline:** Hemoglobin, hematocrit, and platelet count.
* **Ongoing:** Monitor for signs of occult bleeding (black tarry stools, coffee-ground emesis) and tinnitus.
* **Periodic:** Renal function (BUN/SCr) in patients on long-term therapy.
## Clinical Pearls
* **Enteric Coating:** Does not prevent GI ulcers occurring via systemic prostaglandin inhibition but can reduce local irritation.
* **ACS Note:** In acute settings, use non-enteric coated, chewable aspirin to achieve rapid systemic levels; if only enteric-coated is available, chew it.
* **Surgery:** Generally held 5–7 days prior to elective surgery depending on clinical risk vs. bleeding risk (consult specialty guidelines).
* **Uncertainty:** Dosing protocols for secondary prevention can vary by institution and patient risk profile (e.g., 75mg vs 81mg vs 100mg preparations).
***
**Educational Disclaimer:** This information is for educational purposes only. Always consult current institutional protocols, local clinical guidelines, and the full prescribing information (package insert) before prescribing or administering medication.
